CIK 0002070849 · Non-accelerated filer<br>Emerging growth company
BillionToOne, Inc.
Sign in to watch- Ticker
- BLLN
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811082020
- Phone
- 650-460-2551
- Business address
- 1035 O'BRIEN DRIVE, MENLO PARK, CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $26,737,121
- in 19 filings, $26.7M under 10b5-1 plans
Net −$26,737,121. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-03 | Atay Oguzhan Chairman and CEO | Sale 10b5-1 | −82 | $139.20 | $11K | 0 |
| 2026-08-03 | Atay Oguzhan Chairman and CEO | Sale 10b5-1 | −6,250 | $137.37 | $859K | 168,750 |
| 2026-08-03 | Atay Oguzhan Chairman and CEO | Sale 10b5-1 | −6,250 | $137.37 | $859K | 162,500 |
| 2026-08-03 | Atay Oguzhan Chairman and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −20,000 | $2.80 | $56K | 555,000 |
| 2026-08-03 | Atay Oguzhan Chairman and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −6,250 | $2.80 | $18K | 548,750 |
| 2026-08-03 | Atay Oguzhan Chairman and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −6,250 | $2.80 | $18K | 542,500 |
| 2026-07-31 | Sakakibara Shan Riku Chief Product Officer | Sale 10b5-1 | −4,000 | $140.21 | $561K | 200,000 |
| 2026-07-16 | Johnson Nancy JoAnn See Remarks | Sale 10b5-1 | −2,133 | $126.98 | $271K | 18,966 |
| 2026-07-16 | Johnson Nancy JoAnn See Remarks | Sale 10b5-1 | −5,559 | $127.89 | $711K | 13,407 |
| 2026-07-16 | Johnson Nancy JoAnn See Remarks | Sale 10b5-1 | −5,601 | $128.96 | $722K | 7,806 |
| 2026-07-16 | Johnson Nancy JoAnn See Remarks | Sale 10b5-1 | −906 | $129.78 | $118K | 6,900 |
| 2026-07-13 | Tsao David Chief Technology Officer | Option exercise 10b5-1 | +10,000 | $2.80 | $28K | 11,000 |
| 2026-07-13 | Tsao David Chief Technology Officer | Option exercise 10b5-1 | +10,000 | $2.80 | $28K | 21,000 |
| 2026-07-13 | Tsao David Chief Technology Officer | Sale 10b5-1 | −1,102 | $122.90 | $135K | 19,898 |
| 2026-07-13 | Tsao David Chief Technology Officer | Sale 10b5-1 | −2,477 | $123.84 | $307K | 17,421 |
| 2026-07-13 | Tsao David Chief Technology Officer | Sale 10b5-1 | −2,415 | $124.90 | $302K | 15,006 |
| 2026-07-13 | Tsao David Chief Technology Officer | Sale 10b5-1 | −3,185 | $125.85 | $401K | 11,821 |
| 2026-07-13 | Tsao David Chief Technology Officer | Sale 10b5-1 | −821 | $126.89 | $104K | 11,000 |
| 2026-07-13 | Tsao David Chief Technology Officer | Sale 10b5-1 | −1,138 | $122.84 | $140K | 9,862 |
| 2026-07-13 | Tsao David Chief Technology Officer | Sale 10b5-1 | −2,274 | $123.71 | $281K | 7,588 |
Page 12 of 32 · 639 trades